Free shipping over $25 Start Shopping
$25+ get 10% off, $50+ get 15% off,  $100+ get 20% off your order

Management of Alzheimer’s Disease

WITH ANKASCIN – CLINICAL RESEARCH

Dr. Pan’s group recently completed a clinical study to evaluate the use of Ankascin to manage the symptoms of Alzheimer’s disease.

HOW IT WORKS

Antioxidants protect the body against the harmful effects of waste products produced by our cells. These waste products create a state known as oxidative stress, which is a major aspect of both cardiovascular disease and Alzheimer’s disease. Reducing such stress can slow the development of both disorders. Monascin and ankaflavin act as powerful antioxidants. Recent work from Dr. Pan’s lab showed that monascin prevents oxidation of amyloid beta protein, which is a first step in its aggregation into amyloid plaques43. Furthermore, monascin assists the cells of the body to increase the production of various antioxidant genes that also contribute to the protective effect. The net effect of these actions is to reduce both the inflammation and toxicity associated with amyloid beta buildup. Ankaflavin also acts as an anti-inflammatory agent through different mechanisms44. It activates the cellular oxidative stress pathway, which leads cells to respond by producing large quantities of natural antioxidants17.

STUDY


CLINICAL STUDY FOR THE EFFECT OF ANKASCIN 568 IN ALZHEIMER’S PATIENTS

AUTHORS: Tzu-Ming Pan, Ya-Wen Hsu and colleagues

JOURNAL: Submitted for publication

PUBLICATION YEAR: 2018

DESIGN: Placebo-controlled clinical study

POPULATION: 10 patients with mild to moderate Alzheimer’s disease

DOSE: 440 mg of Ankascin per day

DURATION: 10 months

EVALUATION: Monthly

RESULTS: After 9 months of treatment, patients receiving Ankascin showed fewer signs of dementia as compared to a decline in the control group. Ankascin patients also exhibited less distress and agitation, in addition to a reduction in blood LDL cholesterol and triglycerides.

KEY CONCLUSIONS: Ankascin may be effective in managing symptoms associated with Alzheimer’s disease.


Figure 10. Effect of Ankascin treatment on a clinical test for Alzheimer’s disease.

REFERENCE

17. Hsu, W.-H. H., Lee, B.-H. H., Huang, Y.-C. C., Hsu, Y.-W. W. and Pan, T.-M. M. (2012). Ankaflavin, a novel Nrf-2 activator for attenuating allergic airway inflammation. Free Radical Biology and Medicine 53: 1643–1651

43. Shi, Y. C., Pan, T. M. and Liao, V. H. C. (2016). Monascin from Monascus-Fermented Products Reduces Oxidative Stress and Amyloid-β Toxicity via DAF-16/FOXO in Caenorhabditis elegans. Journal of Agricultural and Food Chemistry 64: 7114–7120 iorit

44. Hsu, L.-C., Hsu, Y.-W., Liang, Y.-H., Kuo, Y.-H. and Pan, T.-M. (2011). Anti-tumor and Anti-inflammatory Properties of Ankaflavin and Monaphilone A from Monascus purpureus NTU 568. Journal of Agricultural and Food Chemistry 59: 1124–1130 ity50 \lsdlo

Avatar

About The Author

Ph.D

You might also like to read